Screener
Vir Biotechnology, Inc. VIR Payment of contingent consideration in excess of acquisition date fair value
Payment of contingent consideration in excess of acquisition date fair value at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue.
The source filing: Vir Biotechnology, Inc.’s 10-K, filed February 23, 2026. Open the filing →
- Filed
- Feb 23, 2026, 5:27 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-010749
FAQ
- What is Vir Biotechnology, Inc.'s payment of contingent consideration in excess of acquisition date fair value?
- Vir Biotechnology, Inc. (VIR) reported payment of contingent consideration in excess of acquisition date fair value of -$4.29M in Q4 2025.
- What does payment of contingent consideration in excess of acquisition date fair value mean?
- This metric tracks cash payments made for contingent consideration that exceed the fair value initially recorded at the acquisition date. It highlights the actual cash outflow associated with successful performance milestones or earn-outs in M&A transactions. Investors monitor this to evaluate the true cost of acquisitions relative to initial valuation estimates.
Ask your AI about Vir Biotechnology, Inc.'s payment of contingent consideration in excess of acquisition date fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude